Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Dementia & Alzheimer’s — Weekly Report — October 5, 2026

Home/Health Insights/Dementia & Alzheimer's — October 5 – October 12, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Dementia & Alzheimer's
Updated Monday · November 16, 2026
Dementia & Alzheimer's · October 5 – October 12, 2026

Dementia & Alzheimer's
Weekly Report

This week's data 15 new clinical trials registered across 9 countries, with 951 trials actively recruiting patients worldwide.
Week of October 5 – October 12, 2026
  • 15 new clinical trials registered across 9 countries.
  • 951 trials actively recruiting patients worldwide.
  • Notable trial: Leveraging Interventions for Caregiver Growth, Health, Training, Empowerment and Navigation: Comparing Group Behavior... (450 patients).
  • 319 new research papers published.
  • Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 5 – October 12, 2026
New Trials This Week
15.
registered Oct 5–Oct 12
Recruiting Now
951
active trials seeking patients
Countries
9
with active trials this week
Papers Published
319
new studies this week
Phase 3 Trials
0
late-stage trials this week
Fig. 01

Trials by country

Count · October 5 – October 12, 2026
Taiwan
12
United States
6
South Korea
2
Poland
2
Not specified
1
Canada
1
United Kingdom
1
Turkey (Türkiye)
1
Spain
1
0 3 6 9 12
total
Fig. 02

Trials by phase

Distribution · October 5 – October 12, 2026

New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

15 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Negotiation Training for Family Caregivers of People With Alzheimer's Disease Dementia & Alzheimer's · Northwestern University (NCT07859540) Other Not Yet Recruiting 200 United States
02 Mindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers Dementia & Alzheimer's · Drexel University (NCT07859865) Other Active Not Recruiting 36 United States
03 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies Dementia & Alzheimer's · Novartis Pharmaceuticals (NCT07868328) Phase 2 Not Yet Recruiting 48 N/A
04 Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia Dementia & Alzheimer's · ReadyCure Inc. (NCT07863011) Other Recruiting 30 South Korea
05 A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease Dementia & Alzheimer's · Eisai Inc. (NCT07864623) Other Not Yet Recruiting 270 United States
06 Peer Support for Family Caregivers of Older Adults Living With Dementia Dementia & Alzheimer's · Ohio State University (NCT07868718) Phase 2 Not Yet Recruiting 344 United States
07 SENSE-Brain Health Pro for Older Adults With Sensory Loss Dementia & Alzheimer's · Université de Montréal (NCT07856888) Other Not Yet Recruiting 300 Canada
08 A Grief Support App for Adults Experiencing Bereavement Dementia & Alzheimer's · Medical Research Council Cognition and Brain Sciences Unit (NCT07862244) Other Not Yet Recruiting 80 United Kingdom
09 CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI Dementia & Alzheimer's · University of California, San Francisco (NCT07866768) Other Not Yet Recruiting 28 United States
10 Acceptance and Commitment Therapy-Based Anger Management Training in Forensic Psychiatry Patients Dementia & Alzheimer's · Hatice Polat (NCT07857148) Other Completed 60 Turkey (Türkiye)
11 An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan Dementia & Alzheimer's · Eisai Taiwan Inc. (NCT07869264) Other Not Yet Recruiting 100 Taiwan
12 Leveraging Interventions for Caregiver Growth, Health, Training, Empowerment and Navigation: Comparing Group Behavioral Interventions to Improve Dementia Caregiver Strain Dementia & Alzheimer's · Massachusetts General Hospital (NCT07868588) Other Not Yet Recruiting 450 United States
13 A HYBRID EFFECTIVENESS-IMPLEMENTATION AND COST-UTILITY EVALUATION OF A SUPPORT PROGRAMME FOR INFORMAL CARERS OF PEOPLE WITH DEMENTIA IN PRIMARY CARE (ESCUIDAR2) Dementia & Alzheimer's · Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (NCT07861789) Other Not Yet Recruiting 200 Spain
14 Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease Dementia & Alzheimer's · Neumous Inc. (NCT07869238) Other Recruiting 10 South Korea
15 Cervical Lymphatic Microsurgery in Alzheimer's Disease Dementia & Alzheimer's · Daniel Maliszewski (NCT07857759) Other Recruiting 30 Poland
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
donepezil Death 208
memantine Death 129
rivastigmine Death 292
galantamine Fall 32
lecanemab Amyloid Related Imaging Abnormality-oedema/effusion 202

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

319 papers

Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Perfusion quality does not necessarily predict ultrastructural preservation after hyperosmotic brain perfusion. Slaughter A et al. 10.1080/01913123.2026.2745999
View abstract

Perfusion fixation is widely used in neuroscience to prepare mammalian brain tissue for histological and ultrastructural analysis. Perfusion protocols are commonly assessed using macroscopic indicators such as gross appearance and neuroimaging, which assess the extent to which perfusate has been distributed throughout the brain. There is a critical need to determine to what extent these metrics can accurately predict high-quality ultrastructural preservation, particularly as new perfusion protocols are developed for connectomics. In this technical report, we describe evidence that these two measures can be decoupled by the addition of dehydrating agents to the perfusate solution. In three human brain donors and one canine brain donor perfused with a fixative solution containing 10% mannitol and 10% polyethylene glycol 35 kDa, macroscopic and radiological indicators of perfusion quality appeared adequate or favorable. However, electron microscopy revealed expanded extracellular space, shrunken cellular processes, and distorted cell membranes, consistent with an osmotic shock artifact resulting from severe hyperosmotic dehydration. Similar ultrastructural artifacts were observed in a canine brain donor perfused with 20% mannitol in 20% neutral buffered formalin without PEG. We compare these ultrastructural findings with findings from previously reported cases perfused with standard neutral buffered formalin without osmotic additives. These findings illustrate a risk of optimizing brain perfusion protocols designed to preserve neural circuitry based on macroscopic or radiological perfusion quality metrics alone, since these metrics can be satisfied while the ultrastructure is severely compromised.

Ultrastructural pathology 2026 Oct 11 PubMed
02 Structural Vulnerability and the Pandemic: Widening Gaps in Nursing Home Antipsychotic Prescribing. Funk AJ et al. 10.1177/07334648261496578
View abstract

To assess whether national reductions in antipsychotic prescribing in U.S. nursing homes were shared equitably or masked widening gaps between top and bottom performers, we examined distributional trends across facilities from 2013 to 2023 using national facility-level data (CMS Provider Data Catalog; LTCFocus). We modeled long-stay antipsychotic measure performance using linear quantile mixed regression, assessed mobility across performance quartiles with transition matrices, and evaluated facility characteristics associated with trajectories. From 2013 to 2019, prescribing fell across all quantiles, with the steepest reductions among the worst performers, narrowing gaps with the best. After 2020, progress diverged: lower-performing facilities experienced sharp setbacks while top performers maintained gains. Mobility analyses showed entrenched disadvantage, with bottom-quartile facilities disproportionately likely to remain there. Higher Medicaid share predicted decline, whereas higher star ratings predicted improvement. The pandemic reversed earlier equity gains, amplifying structural disparities and exposing unequal capacity to sustain improvement.

Journal of applied gerontology : the official journal of the Southern Gerontological Society 2026 Oct 11 PubMed
03 ATRI LIMS: a cloud-native open-source laboratory information management system for biomarker-driven Alzheimer's disease clinical trials. Jimenez-Maggiora GA et al. 10.1093/jamiaopen/ooag198
View abstract

OBJECTIVES: This article summarizes the architecture, design principles, and implementation strategy of the ATRI Laboratory Information Management System (LIMS), a cloud‑native, open‑source platform supporting biomarker‑driven Alzheimer's disease (AD) clinical research. The system addresses challenges associated with managing large‑scale, multimodal biomarker, and biobanking data across multisite studies. METHODS: The ATRI LIMS employs a Model-View-Controller architecture implemented in Django, with Single‑Page Application interfaces built in ReactJS. A hybrid database model integrates a normalized core schema with study‑specific extensions. Deployment on Amazon Web Services incorporates multifactor authentication, encryption, and a web application firewall. Regulatory support is provided through audit trails and electronic signatures. Development relied on collaboration between informatics engineers and laboratory personnel, with user acceptance testing guiding workflow and interface refinement. RESULTS: As of February 2026, the ATRI LIMS supports seven clinical trials and observational studies and manages more than 1.2 million biospecimens. The platform synchronizes biospecimen metadata and assay outputs with clinical datasets, improves operational efficiency through automated workflows and quality control, and facilitates compliant sample sharing for secondary research. AI‑assisted development accelerated feature delivery while maintaining code quality. DISCUSSION: The ATRI LIMS offers a scalable, adaptable informatics framework for biomarker‑intensive AD research. Its modular design, cloud‑native architecture, and comprehensive data management capabilities support accurate specimen tracking and coordinated data integration. An open-source release is planned to enable adoption and adaptation by other research programs. CONCLUSIONS: The ATRI LIMS enhances informatics infrastructure for modern AD research by enabling scalable, efficient, and compliant biomarker and biospecimen workflow management.

JAMIA open 2026 Oct PubMed
04 Cerebral Hemodynamic Changes in Older Adults With Cognitive Complaints According to the Presence of Peripheral Artery Disease. Noh S et al. 10.1002/agm2.70121
View abstract

OBJECTIVE: As a systemic expression of atherosclerosis, peripheral artery disease (PAD) has the potential to alter cerebral hemodynamics in elderly individuals presenting with cognitive concerns. However, how PAD status shapes the longitudinal trajectory of cerebral hemodynamics has not been well characterized. METHODS: We conducted a single-center longitudinal observational study enrolling 132 participants (21 controls, 39 mild cognitive impairment, 72 mild Alzheimer's disease). All participants underwent transcranial Doppler (TCD) ultrasonography, ankle-brachial index (ABI) measurement, brain MRI, and cognitive assessments at baseline and follow-up (~13.45 months). PAD was defined as ABI < 0.90. Bilateral mean flow velocity (MFV), pulsatility index (PI), and resistance index (RI) of the middle cerebral artery (MCA) were tracked longitudinally across both time points. RESULTS: PAD was identified in 13 participants (9.8%). Baseline TCD parameters, vascular risk factors, white matter lesions on brain MRI, and cognitive measures were comparable between groups. At follow-up, the PAD group showed significantly higher MCA MFV after age adjustment (left  < 0.001; right  = 0.005). MFV increased in the PAD group (left +16.45 cm/s) but decreased in the non-PAD group (left -3.37 cm/s), with a significant between-group difference. PI and RI did not change in either group. Cognitive and functional outcomes were similar across groups throughout the study. CONCLUSION: These findings identify PAD as a condition associated with progressive MCA MFV elevation in the context of preserved cognition, implying that subclinical cerebrovascular changes are detectable by TCD before overt clinical worsening. Future research involving larger cohorts and extended follow-up is required to determine whether such hemodynamic changes forecast eventual cognitive deterioration.

Aging medicine (Milton (N.S.W)) 2026 Oct 10 PubMed
05 The Gut-Brain Axis and Neurodegenerative Diseases: From Mechanistic Pathways to Therapeutic Interventions. Lin W et al. 10.1007/s12602-026-11246-w
View abstract

As the global population ages, the incidence of neurodegenerative diseases (NDDs) has increased. Neurodegenerative diseases have complex pathogenesis and currently lack fundamental treatment methods. The gut-brain axis (GBA) participates in the pathogenesis of NDDs through bidirectional communication between the gut microbiota and the central nervous system (CNS). This review systematically introduces the pathogenic characteristics of representative NDDs such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS), as well as the association mechanisms between these diseases and GBA. The pathogenic characteristics of NDDs are closely related to changes in the composition of the gut microbiota and differences in gut microbiota metabolites (such as short-chain fatty acids (SCFAs), neurotransmitters, tryptophan metabolites, etc.). These changes influence the CNS through multiple pathways, including neuroendocrine, vagus nerve, and immune regulation, ultimately contributing to the onset and progression of the diseases. Furthermore, we have collected and summarized preclinical and clinical evidence from recent years regarding therapeutic interventions based on the GBA mechanism, including probiotics, prebiotics, and fecal microbiota transplantation (FMT). Nevertheless, major knowledge gaps remain, particularly regarding causality between gut microbiota changes and NDDs, the underlying molecular mechanisms, and the clinical efficacy of GBA-targeted therapies. This article aims to review the mechanisms of the interaction between the gut microbiota and the brain in neurodegenerative diseases, and based on the existing experimental evidence, provide theoretical basis and future development directions for future prevention and treatment strategies targeting GBA.

Probiotics and antimicrobial proteins 2026 Oct 10 PubMed
06 Characterizing hippocampal activation during pattern separation with multi-echo fMRI in cognitively normal older adults. Solar KG et al. 10.1007/s11682-026-01208-9
View abstract

Hippocampal hyperactivity, detected with mnemonic similarity task (MST) fMRI, is both a promising marker of risk and a probable driver of degeneration in Alzheimer's disease (AD). However, implementation of such fMRI in interventional research is limited by long scan times and the absence of a framework for identifying prospective participants with hyperactivity who could be targeted with therapeutic approaches aimed at reducing this activity. We used multi-echo fMRI during the MST, an episodic memory task previously shown to engage hippocampal subfields CA3 and dentate gyrus (DG), to characterize activity profiles in 33 cognitively normal older adults. We compared MST-related CA3 and DG activation and behavioural performance across subsets of eight task runs. Behavioural and activation effects were equivalent for the first set of four runs (Runs-A) and the second set (Runs-B), suggesting that robust data can be obtained with four runs. Left and right CA3 + DG activation did not differ. We provide an exemplar framework for the derivation of a threshold for single-participant classification of elevated hippocampal activation as an indicator of AD risk in cognitively normal older individuals. Scalable (~22 min) multi-echo MST fMRI robustly captures hippocampal activation and provides a framework for individual-level characterization of hippocampal function in cognitively normal older adults. This enables individualized detection of elevated hippocampal activation as a modifiable risk factor and may guide enrolment into prevention trials targeting preclinical AD.

Brain imaging and behavior 2026 Oct 10 PubMed
07 Integrative Transcriptomic and Interactome Analyses Prioritize Candidate Genes for Alzheimer's Disease. Maglio GM et al. 10.1007/s12035-026-06258-0
View abstract

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder characterized by complex molecular alterations and diverse cognitive, behavioral, and neuropsychiatric manifestations. Although transcriptomic studies have identified several pathways associated with AD, the integration of molecular signatures with disease-related phenotype annotations and pathological aging remains incompletely understood. Therefore, this study aimed to integrate transcriptomic profiling, protein-protein interaction (PPI) network analysis, pathological aging assessment, and curated clinical phenotype annotations to prioritize candidate molecular signatures associated with AD. Differential expression analyses and network-based approaches were applied to publicly available transcriptomic datasets derived from distinct brain regions. Candidate genes and pathways were prioritized through interactome reconstruction, functional enrichment analyses, cluster-based analyses, and independent validation in an external dataset. In addition, transcriptomic signatures were integrated with curated clinical phenotype annotations using a knowledge-based gene overlap strategy. The analysis identified molecular signatures associated with neuroinflammatory signaling, synaptic dysfunction, endocytosis, and pathological aging. Pathways related to MAPK, PI3K/Akt, NF-κB, and TGF-β1 signaling emerged as candidate dysregulated pathways in AD. Comparative analyses of physiological aging and the AD aging comparison enabled the prioritization of candidate genes potentially more closely associated with the AD condition than with aging alone, including FOS and TAB2. Independent validation reinforced the reproducibility of several prioritized genes, including GFAP, CXCR4, CCL2, HSPA1A, FCGR2A, TLR2, CD44, TLR4, FOS, TAB2, CDC42, and SH3GL2. Integration with curated clinical phenotype annotations suggested partially overlapping molecular signatures across neuropsychiatric and cognitive phenotype annotations in AD. Together, these findings demonstrate the utility of integrative bioinformatics approaches for prioritizing candidate genes, pathways, and molecular signatures associated with AD. This systems-level framework may contribute to future mechanistic studies aimed at understanding the molecular heterogeneity of AD and its associated phenotypic complexity.

Molecular neurobiology 2026 Oct 10 PubMed
08 Glyceryl tribenzoate, a flavoring agent, stimulates hippocampal plasticity and protects memory via PPARα. Patel DR et al. 10.1016/j.neuint.2026.106270
View abstract

Glyceryl tribenzoate (GTB) or tribenzoin is a flavoring agent with characteristic anti-microbial property. We have already delineated GTB's immunomodulatory role via the enrichment of regulatory T cells in mouse models of multiple sclerosis and anti-neuroinflammatory role via the reduction of glial activation in a monkey model of Parkinson's disease and a mouse model of Huntington's disease. However, its role has never been explored in Alzheimer's disease (AD), the most common neurodegenerative disorder in human. This study underlines the importance of GTB in promoting the growth and function of hippocampal neurons via upregulation of plasticity-associated genes, enrichment of dendritic spines and stimulation of inotropic calcium influx. Accordingly, oral GTB improved hippocampal plasticity and protected memory and learning in 5xFAD mice. Similarly, GTB treatment also reduced cerebral plaque load and increased the life span of aged 5xFAD mice. Interestingly, we observed that peroxisome proliferator-activated receptor alpha (PPARα), a nuclear hormone receptor, served as a receptor of GTB. Consequently, GTB was shown to improve hippocampal plasticity and increase cognitive functions in 5xFAD, but not 5xFAD/Ppara-null, mice, indicating an important role of PPARα in GTB-mediated neuroprotection. These results suggest that oral GTB may have therapeutic importance for improving hippocampal functions in AD patients.

Neurochemistry international 2026 Oct 10 PubMed
09 Waterless versus soap-and-water perineal hygiene in fully dependent hospitalized patients: a multicenter randomized trial. Gazineo D et al. 10.1016/j.jhin.2026.09.032
View abstract

BACKGROUND: This study evaluated the microbiological effectiveness and organizational impact of waterless perineal hygiene compared with traditional soap-and-water cleansing in fully dependent hospitalized patients, addressing a gap in evidence within acute care settings. METHODS: This multicenter, randomized, open-label superiority trial was conducted in 10 medical and geriatric wards across four hospitals in Northern Italy. Fully dependent adult inpatients were randomized 1:1 to waterless hygiene or standard soap-and-water care. The primary outcome was the proportion of participants achieving a ≥90% reduction in microbial load between pre- and post-procedure perineal swabs. Secondary outcomes included procedure duration, patient and healthcare professional satisfaction, and agreement between evaluations. RESULTS: A total of 468 participants were analyzed (239 control; 229 experimental). The experimental procedure achieved a higher proportion of ≥90% microbial reduction compared with standard care (47.2% vs 37.2%; p=0.030), corresponding to an absolute risk difference of 9.9% (95% CI 1.0-18.8) and a risk ratio of 1.27 (95% CI 1.02-1.57). Procedure duration was similar between groups (median 10 vs 11 minutes; p=0.311). Satisfaction was high in both groups, with more favorable perceptions of fragrance and overall hygiene in the experimental group. CONCLUSIONS: Waterless perineal hygiene demonstrated greater immediate microbiological cleansing effectiveness than standard soap-and-water hygiene without increasing procedure time. Further studies are needed to determine whether these microbiological findings translate into improved clinical outcomes, including healthcare-associated infections.

The Journal of hospital infection 2026 Oct 10 PubMed
10 Beyond the brain-centric view: A systems physiology framework for exercise-induced neuroprotection in Alzheimer's disease. Changjian W et al. 10.1016/j.expneurol.2026.116058
View abstract

Alzheimer's disease (AD) is regarded as a multifactorial disease that combines central pathological changes and peripheral organ dysfunction. Its core features include Aβ protein deposition, tau protein pathology, synaptic dysfunction, and neuroinflammation. Exercise has been proven to be one of the most effective non-pharmacological intervention measures. However, its mechanism of action in AD has not been fully elucidated from the traditional brain-centered research perspective. Moreover, most existing studies focus on isolated organ systems or a single signaling pathway, failing to fully reflect the overall peripheral-cerebral physiological interaction mechanism required for neuroprotective effects of exercise. This article provides a structured narrative synthesis of current evidence regarding how exercise may influence AD-related pathological processes through multiple peripheral organ systems. It clarifies the communication mechanisms between these systems and the central nervous system through endocrine, immune, metabolic, neural, and vascular pathways. The study shows that exercise functions by coordinating the regulation of peripheral physiological functions, rather than relying on a single target mechanism. Exercise can regulate multiple signaling pathways such as muscle-brain, gut-brain, liver-brain, adipose-brain, bone-brain, and immune-brain, improving overall metabolic flexibility, inflammation regulation, vascular function, and neuroimmune homeostasis; these peripheral adaptive changes further act on the central nervous system, regulating blood-brain barrier(BBB) integrity, microglial cell activity, neuronal energy metabolism, neurovascular coupling, and synaptic plasticity. In summary, the neuroprotective effect induced by exercise stems from the integration of multiple systems' physiology, rather than isolated molecular signal transduction. This review synthesizes current evidence on exercise-induced peripheral-central interactions in AD from a systems physiology perspective, highlighting the significance of integrating peripheral biomarkers, multi-organ interactions, and central outcomes. It provides a theoretical framework for future personalized and mechanism-oriented exercise intervention studies.

Experimental neurology 2026 Oct 10 PubMed
11 Neuroimmune State Configurations at the Amyloid-Tau Interface in Alzheimer's Disease: A Testable Framework. Zhang K et al. 10.14336/AD.2026.0888
View abstract

Neuroimmune mechanisms are central to Alzheimer's disease (AD), but a single continuum of "more inflammation" does not explain why similar amyloid-β (Aβ) and tau burdens are associated with different clinical trajectories, tissue responses, and treatment risks. We present a testable neuroimmune-state framework that integrates, rather than replaces, the AT(N) system, cellular-phase models, and transcriptional descriptions of disease-associated microglia and reactive astrocytes. The framework treats neuroimmune states as multidimensional, regionally heterogeneous configurations defined by pathological substrate, cellular program, biological target, vascular and aging context, and measurable patient-level readouts. We distinguish four meanings of the amyloid-tau interface: a biomarker interface, a spatial tissue interface, a cellular-state interface, and a clinical-progression interface. We then examine the hypothesis of phagocytic target switching, in which clearance pathways that support plaque compaction or debris removal may, under selected tau- and complement-rich conditions, contribute to removal of stressed but potentially functional synapses. We explicitly separate evidence from longitudinal human studies, cross-sectional biomarkers, human genetics, postmortem tissue, animal models, and in vitro systems. Current biomarkers cannot yet assign patients to validated discrete neuroimmune states; proposed state readers should therefore be probabilistic, allow regional coexistence and parallel vascular-immune trajectories, and be tested for incremental value beyond established AD biomarkers and co-pathologies. Finally, we organize immune-directed interventions by clinical evidence level and frame stage matching as a research strategy rather than a treatment algorithm. The model is useful only if its predictions can be prospectively supported or falsified.

Aging and disease 2026 Oct 9 PubMed
12 A Clearance-Repair-Activation Framework for Alzheimer's Disease: A Perspective and Validation Roadmap. Yang Y et al. 10.14336/AD.2026.1040
View abstract

Alzheimer's disease (AD) is a heterogeneous clinicobiological syndrome involving impaired protein clearance, neuroinflammation, synaptic and cellular injury, network dysfunction, and progressive functional decline. Amyloid-directed antibodies provide an evidence-based treatment backbone for selected patients with early symptomatic AD, but adjunctive strategies may be needed to address other disease mechanisms. This Perspective proposes a clearance-repair-activation framework for hypothesis-driven research. Clearance includes established pharmacological treatment and risk management as well as investigational drainage approaches; lymphaticovenous anastomosis (LVA) and deep cervical lymphaticovenous anastomosis (dcLVA) are considered only as research options within this broader domain. Repair includes neural stem-cell (NSC), induced pluripotent stem-cell-derived, engineered-cell, and secretome-based strategies, for which AD evidence remains predominantly preclinical. Activation encompasses invasive and non-invasive stimulation, sensory entrainment, neurofeedback, brain-computer interface (BCI) monitoring, and cognitive rehabilitation; BCI is positioned mainly as an experimental monitoring and adaptive rehabilitation platform. We define falsifiable links between clearance and repair readiness and between repair markers and activation responsiveness, consider adaptive and parallel alternatives to fixed sequencing, and integrate disease stage, heterogeneity, regulation, and combination-trial design. Informatics is limited to trial infrastructure and safety governance. The validation roadmap specifies success criteria, stop rules, interaction testing, clinically meaningful outcomes, and long-term surveillance.

Aging and disease 2026 Oct 8 PubMed
13 Description of a visuospatial mislocation symptom in dementia with Lewy Bodies. Grancho J et al. 10.1007/s13760-026-03213-7 Acta neurologica Belgica 2026 Oct 10 PubMed
14 Treadmill exercise impedes cognitive decline in type 2 diabetic rats by improving mitochondrial function and modulating the TGF-β/Smad-3 pathway. Padhy DS et al. 10.1007/s00424-026-03216-6
View abstract

Chronic hyperglycemia and cerebral insulin resistance are the major contributors to cognitive impairment in the ageing population. Due to the increased number of the worldwide type - 2 diabetic mellitus (T2DM) population, the prevalence of cognitive decline and dementia has also increased. It is well documented that moderate aerobic exercise dramatically improves cognitive function in individuals with diabetes. However, the impact of exercise on T2DM-associated cognitive decline modulating TGF-β/Smad-3 signalling is yet to be explored. In this study, we assessed the impact of treadmill exercise on cognitive health in a preclinical model of T2DM, focusing on neuroinflammation, mitochondrial function, and the TGF-β/Smad-3 signalling pathway. To develop an experimental type - 2 diabetic model, rats were fed a high-fat diet (HFD), followed by an intraperitoneal injection of a single low dose of streptozotocin (STZ, 35 mg/kg). After confirmation of diabetes, rats underwent moderate-intensity treadmill exercise for 14 weeks. We observed a significant alternation in behavioural patterns in diabetic rats compared to controls, which reversed on exercise treatment. Moreover, chronic Type - 2 diabetes compromises mitochondrial function and increases inflammation in the hippocampal region of the brain. An increase in pro-inflammatory cytokines, such as IL-1β and TNF-α, was observed in the hippocampus of T2DM animals and was reduced by exercise. Oxidative stress is markedly increased in the type - 2 diabetic brain, resulting in compromised mitochondrial function with elevated hippocampal MDA and decreased GSH and ATP levels, which are reversed in the exercise group. Furthermore, we evaluated the role of exercise on TGF-β/Smad-3 signalling in the type - 2 diabetic brain. Exercise suppresses the overexpression of this signalling cascade in the diabetic brain. In summary, moderate-intensity treadmill exercise ameliorated type - 2 diabetes-associated cognitive impairment by decreasing oxidative stress, neuroinflammation, mitochondrial dysfunction and downregulating the TGF-β/Smad-3 signalling pathway.

Pflugers Archiv : European journal of physiology 2026 Oct 10 PubMed
15 Readmission Risk Coming Home After Rehabilitation in a Skilled Nursing Home With Dementia. Carnahan JL et al. 10.1111/jgs.70752
View abstract

BACKGROUND: Community dwelling people living with dementia (PLWD) are more likely to visit a skilled nursing home (SNH) after an acute hospital stay and have a high risk of readmission to the hospital. Staff in SNHs have familiarity with caring for PLWD that may mitigate readmissions, but dementia's role in readmissions for this high risk population remains unclear. METHODS: Using Health and Retirement Study data linked to Medicare claims between 2000 and 2019, this study aimed to investigate the role of dementia in hospital readmissions after a short rehabilitative stay (< 100 days) in the nursing home. Event-level data was analyzed for risk of 30-day hospital readmission following SNH discharge to the community using first Generalized Estimating Equations to estimate individual variables' association with readmission and then constructing a regression model to estimate the risk of readmission to the hospital using adjusted odds ratios. RESULTS: There were 714 readmissions to the hospital out of 4527 discharges to the community following SNH stay (15.8%). A dementia diagnosis identified by Medicare claims, present for 42.2% of the population, was not associated with hospital readmission. Female sex, being married, and living in the Midwest or Western United States were associated with lower odds of readmission. Hospital or emergency department visits in the year prior to the index SNH admission and higher Charlson comorbidity scores were associated with higher odds of post-SNH discharge 30-day readmission. CONCLUSIONS: A formal dementia diagnosis may serve as a signal to SNHs to provide enhanced support in their discharge processes. Intrinsic factors related to the patient's health status such as prior hospital use and comorbidity burden, in addition to social support factors such as marital status, play the greatest role in readmission risk. These characteristics should be recognized and mitigated by discharge planners, policy makers, and insurers making care coverage decisions.

Journal of the American Geriatrics Society 2026 Oct 10 PubMed
16 Coprophagia in Moderately Severe Dementia: Comprehensive Geriatric Assessment, Interdisciplinary Management, and the 5Ms. Ocampo EMH et al. 10.1111/jgs.70776 Journal of the American Geriatrics Society 2026 Oct 10 PubMed
17 Qi-Fu-Yin Attenuates Frailty by Regulating Gut Microbiota and Neuroendocrine Hormones in 5xFamilial Alzheimer's Disease Transgenic Mice. Yang X et al. 10.3791/73003
View abstract

Frailty is a common and debilitating feature of Alzheimer's disease (AD), yet effective therapeutic strategies targeting both cognitive decline and physical frailty remain limited. Qi-Fu-Yin (QFY), a traditional Chinese herbal formulation, has been used to treat aging-related disorders, but its effects on frailty in AD and the underlying mechanisms are unclear. This study aimed to evaluate whether QFY alleviates frailty in 5xFamilial Alzheimer's Disease (FAD) transgenic mice and to explore the potential involvement of gut microbiota and neuroendocrine hormones. Mice were treated with QFY at low (2.8 g/kg), medium (5.6 g/kg), or high (11.2 g/kg) doses, or with donepezil as a positive control, for 194 days. Frailty-related behaviors were assessed using CatWalk gait analysis, grip strength, rotarod, nest-building, and aging scoring. Plasma hormone levels were measured, and fecal gut microbiota composition and function were analyzed by 16S rRNA sequencing and metagenomic analysis. QFY treatment significantly improved gait parameters, grip strength, motor coordination, nesting ability, and reduced aging scores in 5xFAD mice, with effects comparable to or superior to those of donepezil. QFY also restored aberrant levels of estradiol, testosterone, and corticosterone, and reshaped gut microbiota composition, particularly by increasing the abundance of Adlercreutzia, which negatively correlated with senescence and testosterone levels. Functional metagenomics revealed that QFY partially restored disease-associated microbial pathways, including those involved in carbohydrate metabolism and virulence. These findings suggest that QFY alleviates frailty in 5xFAD mice, with effects associated with concurrent modulation of gut microbiota and neuroendocrine function, though causal relationships require further validation. These findings support further investigation of QFY as a potential intervention for AD-associated frailty.

Journal of visualized experiments : JoVE 2026 Oct 9 PubMed
18 Baseline and longitudinal trajectories of peak expiratory flow in relation to incident cognitive impairment among older adults: Evidence from CHARLS. Wang P et al. 10.1177/13872877261494159
View abstract

BackgroundPrevious studies, including CHARLS analyses, have linked lower peak expiratory flow (PEF) with cognitive decline. Evidence regarding incident score-based cognitive impairment, longitudinal PEF patterns, and incremental prediction remains limited.ObjectiveTo examine associations of baseline PEF and exploratory PEF trajectories with incident score-based cognitive impairment and evaluate the incremental predictive value of PEF.MethodsThe primary analysis included 2604 CHARLS participants aged ≥60 years without score-based cognitive impairment at baseline. Cognitive impairment was defined as a global cognitive score ≥1 SD below the wave- and age-specific mean and was not a clinical diagnosis of mild cognitive impairment or dementia. Cox models, sensitivity analyses, prediction analyses, and exploratory trajectory modeling were performed.ResultsOver a median follow-up of 9.0 years, 636 participants developed score-based cognitive impairment. Each 1-SD increase in PEF was associated with lower risk in fully adjusted models (HR = 0.801, 95% CI 0.728-0.880) and after adjustment for baseline cognition (HR = 0.846, 95% CI 0.768-0.930). Nine-year cumulative incidence decreased from 35.6% to 16.6% across PEF quartiles. Adding PEF modestly improved 9-year AUC (ΔAUC = 0.011, p = 0.042). In the exploratory trajectory analysis, the moderate PEF group was not significantly associated with risk versus the high group (HR = 1.294, 95% CI 0.860-1.948), whereas the low PEF group had higher risk (HR = 1.817, 95% CI 1.172-2.817), with no clear graded pattern.ConclusionsLower baseline PEF was associated with wave-specific score-based cognitive impairment, but not under stricter definitions requiring subsequent confirmation with wave-specific or fixed thresholds. PEF trajectories were exploratory, and incremental predictive value was limited.

Journal of Alzheimer's disease : JAD 2026 Oct 10 PubMed
19 Single-cell gene networks nominate IKZF1 as an Alzheimer's disease microglial regulator. Özkurt Ç 10.1177/13872877261496918
View abstract

BackgroundMicroglia drive neuroinflammation in Alzheimer's disease (AD), yet no approved therapy targets this compartment. Human genome-wide association studies consistently implicate innate immune loci in AD risk, establishing microglial transcriptional programs as therapeutically relevant but pharmacologically underexploited targets.ObjectiveWe sought to identify transcription factors (TFs) governing microglial state transitions computationally and to nominate structurally tractable drug repurposing candidates.MethodsWe applied trajectory inference (PAGA), pseudobulk DESeq2, pySCENIC gene regulatory network (GRN) inference, CellChat, and virtual screening of 1962 approved compounds to 236,002 microglial nuclei from 84 donors (SEA-AD atlas).Results was the sole target TF retained under cisTarget v10 motif constraints, with peak regulon activity in LateAD-DAM (pseudotime ρ = + 0.309) and replication in an independent bulk cohort (GSE95587; adjusted p = 0.004). CellChat identified SLIT2→ROBO2 from multiple neuron subtypes (predominantly inhibitory interneurons) as the top predicted pathway to microglia. Tafamidis (→IRF8) and diflunisal (→PPARG) were top virtual screening hits; all evaluated compounds failed the pre-specified selectivity threshold.Conclusions is prioritized as a candidate late-disease microglial TF, supported by six convergent evidence dimensions including independent bulk replication. Tafamidis and diflunisal are low-confidence repurposing hypotheses requiring experimental validation.

Journal of Alzheimer's disease : JAD 2026 Oct 10 PubMed
20 Multi-Dimensional Feature Adaptive Gating Network for Multi-View and Whole-Brain Magnetic Resonance Imaging-Based Alzheimer's Disease Classification. Zhou Y et al. 10.3791/73427
View abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with structural brain alterations detectable by structural magnetic resonance imaging (sMRI). Accurate classification of normal control (NC), mild cognitive impairment (MCI), and AD remains challenging because disease-related changes are subtle, spatially distributed across multiple brain regions, and difficult to interpret in a biologically meaningful manner. Existing deep learning methods often rely on either whole-brain volumetric features or two-dimensional slice-level representations, which may limit the integration of complementary structural information and reduce model interpretability. This study presents a reproducible and explainable deep learning framework, termed the multidimensional feature adaptive gating network (MDFAG-Net), for sMRI-based AD classification and neuroimaging analysis. The framework integrates multidimensional structural MRI representations by combining 2D slice-level features extracted from sagittal, coronal, and axial views using a Vision Transformer backbone with global whole-brain features extracted using a three-dimensional convolutional neural network. An Enhanced Sparse Multiple Instance Learning module is employed to identify informative slices and suppress redundant information in long slice sequences, while an adaptive gating module dynamically fuses multiview and whole-brain features according to sample-specific feature contributions. The framework was evaluated on 842 subjects from the Alzheimer's Disease Neuroimaging Initiative dataset for NC/MCI/AD classification. MDFAG-Net demonstrated competitive classification performance and outperformed representative two-dimensional, three-dimensional, and multibranch comparison models under the same experimental setting. The model achieved an area under the receiver operating characteristic curve of 0.798. Furthermore, Grad-CAM and DeepSHAP analyses revealed anatomically relevant regions associated with AD progression, including the hippocampus, amygdala, posterior cingulate gyrus, parahippocampal gyrus, and ventricular system.

Journal of visualized experiments : JoVE 2026 Oct 9 PubMed
21 Noise or clearance? Reframing plasma amyloid-β variability in Alzheimer's disease as a measurable clearance signal. Ben Brik S 10.1177/13872877261496533
View abstract

Plasma biomarkers, and the amyloid-β 42/40 ratio in particular, are increasingly used to stage Alzheimer's disease and to stratify and monitor clinical trials, on the tacit assumption that a single measurement reflects a stable, steady-state level of pathology. A recent micro-longitudinal study that sampled plasma weekly for five weeks in people with Alzheimer's disease challenged that assumption, reporting that most participants varied by more than half in the amyloid-β 42/40 ratio over that short window. The reflexive response is to treat such movement as measurement noise to be averaged away. Here I argue that a meaningful part of it is unlikely to be noise. In healthy adults the same ratio is among the most stable plasma analytes, so instability concentrated in disease is difficult to attribute to the assay alone. Brain-to-blood clearance of amyloid-β is itself dynamic over days, rising with sleep and falling with fragmentation, apnoea, poor cerebral perfusion, autonomic dysregulation, and sedating or anticholinergic drugs. An instantaneous plasma value therefore partly reports the clearance state of the preceding night. This clearance account is kept distinct from analytical and pre-analytical variance, and from oligomeric amyloid-β dynamics, which are considered separately. The practical problem is not the variance itself but that we measure the molecule without measuring the physiological state that moves it. I propose that an inexpensive, repeatable, bedside index of that state, illustrated here with the Systemic BenBrik Geriatric Score, could be recorded alongside each plasma draw and modelled as a covariate, converting nuisance variance into interpretable signal. The prediction is falsifiable, and a validation design is outlined. This is a hypothesis, not a validated result; the illustrative index used here, the Systemic BenBrik Geriatric Score, is not a validated measure.

Journal of Alzheimer's disease : JAD 2026 Oct 10 PubMed
22 Interaction of physical fitness and resting state functional connectivity on global cognitive function in older adults with mild cognitive impairment. Gu Y et al. 10.1177/13872877261491995
View abstract

BackgroundMild cognitive impairment (MCI) represents a prodromal stage of Alzheimer's disease. Physical fitness, including cardiorespiratory fitness and muscular strength, is associated with cognitive function in older adults. Resting-state functional connectivity (rsFC) is also linked to cognitive function; however, whether physical fitness modifies the association between rsFC and cognitive function remains unclear.ObjectiveTo examine associations of cardiorespiratory fitness and muscular strength with rsFC and their interaction on global cognitive function in older adults with MCI.MethodsA cross-sectional study of 95 older adults with MCI. Cardiorespiratory fitness was estimated by the 400-m walk; muscular strength was indexed using grip strength measured by hand dynamometer. Global cognitive function was indexed by the 13-item Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog-13). Using the Yeo 7-network atlas, we computed rsFC within and between seven canonical networks. Significant rsFC-fitness associations were entered into moderation analyses (X = rsFC, Y = ADAS-Cog-13) with cardiorespiratory fitness or grip strength as moderator, adjusted for covariates. Simple slopes were examined at ±1 SD from the mean of moderator.ResultsParticipants had a mean age of 73.49 years, and 53.7% were female. Cardiorespiratory fitness interacted with rsFC in relation to ADAS-Cog-13, whereas grip strength did not. Specifically, greater limbic-visual (standardized  = -0.22,  = 0.009), limbic-somatomotor ( = -0.20,  = 0.049), and limbic-ventral attention ( = -0.19,  = 0.020) rsFC were associated with better global cognitive function among individuals with higher cardiorespiratory fitness.ConclusionsHigher between-network rsFC is generally associated with worse cognitive function. Thus, higher cardiorespiratory fitness may attenuate the negative association between higher between-network rsFC and global cognitive function in MCI.

Journal of Alzheimer's disease : JAD 2026 Oct 10 PubMed
23 High-intensity transcranial alternating current stimulation improves sleep quality in patients with mild Alzheimer's disease: Findings from the TRANSFORM-AD study. Qiao Y et al. 10.1177/13872877261492561
View abstract

BackgroundHigh-intensity transcranial alternating current stimulation (Hi-tACS) has shown beneficial effects on cognitive function in Alzheimer's disease (AD). However, data on the effects of hi-tACS on sleep quality and emotional state in patients with AD are still limited.ObjectiveThis study aimed to investigate the influences of hi-tACS on sleep quality and emotional state in AD.MethodsThe TRANSFORM-AD study was a double-blind, randomized-controlled trial that enrolled individuals with mild AD. Participants were randomized to receive hi-tACS group or sham stimulation group, and underwent 30 one-hour sessions of either 40 Hz tACS or sham stimulation over consecutive 15 consecutive days. Pittsburgh sleep quality index (PSQI), Hamilton anxiety Rating Scale (HAMA), Hamilton depression Rating Scale (HAMD) and Quality of life in Alzheimer's Disease scale (QOL-AD) were evaluated at baseline, and the end of the intervention.ResultsAmong 43 participants with complete baseline and post-intervention assessments, Hi-tACS reduced post-intervention PSQI scores compared with sham after adjustment for baseline PSQI (adjusted mean difference, -2.34 points; 95% CI, -3.63 to -1.05; p < 0.001). Baseline-adjusted effects for HAMA (-1.43; 95% CI, -2.89 to 0.02), HAMD (0.44; 95% CI, -1.28 to 2.15), and QOL-AD (2.07; 95% CI, -1.57 to 5.70) were imprecise and included the null.ConclusionHi-tACS improved subjective sleep quality in patients with mild AD. The present secondary analysis did not provide conclusive evidence of effects on anxiety, depression, or quality of life; these exploratory outcomes require confirmation in larger, adequately powered trials.Trial registration:ClinicalTrials.gov, NCT03920826.

Journal of Alzheimer's disease : JAD 2026 Oct 10 PubMed
24 Left Atrial Enlargement Identifies Risk of Stroke Independent of Atrial Fibrillation. Loft JJ et al. 10.1161/JAHA.126.053248
View abstract

BACKGROUND: Left atrial (LA) enlargement has been proposed to increase stroke risk independent of atrial fibrillation (AF), but evidence accounting for AF over time is limited. We tested whether the association between LA enlargement and stroke persist independent of new-onset AF. METHODS: In this observational study, participants from the Copenhagen General Population Study underwent cardiac computed tomography from 2010 through 2018 and were followed until December 2022. LA volume was indexed to body surface area. LA enlargement was defined using sex-specific cutoffs. The primary outcome was incident stroke. Secondary outcomes were incident AF, heart failure, dementia, and all-cause mortality. Individuals with baseline AF were excluded. Hazard ratios (HRs) were estimated using cause-specific Cox models with AF modeled as a time-varying covariate. RESULTS: Among 10 024 individuals (mean age 60 years, 57% women), 684 (6.8%) had LA enlargement. Over a median follow-up of 7.3 years stroke occurred in 356 individuals (3.6%). LA enlargement was associated with a higher absolute risk of stroke (11.1% versus 4.6%, risk difference 6.5% [95% CI, 2.4-10.6]) and an increased hazard (adjusted HR, 1.49 [95% CI, 1.09-2.05]; =0.013), which remained similar after adjustment for incident AF, and in separate models using the CHADS-VA score and P-wave terminal force in lead V1. LA enlargement was also associated with higher risk of AF (HR, 3.77 [95% CI, 3.00-4.73]) and heart failure (HR, 3.59 [95% CI, 2.54-5.06]) but not with dementia or all-cause mortality. CONCLUSIONS: LA enlargement was associated with incident stroke independent of incident AF, supporting LA enlargement as a marker of thromboembolic risk.

Journal of the American Heart Association 2026 Oct 10 PubMed
25 Introduction to the Special Issue on Building Capacity and Diversity in the Aging Workforce: The NIA Advancing Diversity in Aging Research (ADAR) Through Undergraduate Education Program. Thorpe RJ Jr et al. 10.1177/00914150261496564
View abstract

The following collection of papers represents some of the work produced by Advancing Diversity in Aging Research programs during the past few years. Some papers address training program outcomes, whereas other papers demonstrate the breadth and depth of scholarship produced by different training programs.

International journal of aging & human development 2026 Oct 10 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Dementia & Alzheimer's
  • Week: October 5 – October 12, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:51 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —